Position in ACET
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$439,706
+$58,346 QoQ
Shares Held
50,892
-9.1% QoQ
Ownership
0.544%
of shares outstanding
% of Portfolio
0.44%
of 13F equity value
Holder Rank
#24
of 56 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ACET Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Rangeley Capital, LLC holds $27,388,910 across 46 Biotechnology names. ACET ranks #17 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRTA |
Prothena Corp Public Ltd Co
|
417,270 | $4,085,073 | |
| 2 | ABUS |
Arbutus Biopharma Corp
|
500,000 | $2,400,000 | |
| 3 | ABVX |
Abivax S.A.
|
13,000 | $1,732,380 | |
| 4 | TBPH |
Theravance Biopharma, Inc.
|
99,500 | $1,691,500 | |
| 5 | RLYB |
Rallybio Corp
|
104,850 | $1,677,600 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
33,700 | $1,629,336 | |
| 7 | JANX |
Janux Therapeutics, Inc.
|
97,978 | $1,504,942 | |
| 8 | ARVN |
Arvinas, Inc.
|
175,590 | $1,459,152 |
All Filings in ACET
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $439,706 | 50,892 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $381,360 | 56,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $210,508 | 25,001 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $60,750 | 75,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||